ABOUT US
Our history
Genenta (Nasdaq: GNTA) is a clinical stage immuno-oncology company developing a proprietary hematopoietic stem cells therapy for the treatment of a variety of solid tumor cancers. Genenta’s first in class product candidate is Temferon™, which is designed to allow the expression of immune-therapeutic payloads within the tumor microenvironment by bone marrow derived myeloid cells and enable a durable and targeted response. Genenta has completed a Phase 1 trial for newly diagnosed Glioblastoma Multiforme patients with an unmethylated MGMT gene promoter, which suggests the potential reprogramming of the tumor microenvironment and inhibiting of myeloid induced tolerance, while allowing the induction of T cell responses, potentially breaking immune tolerance. Genenta has initiated in Q4 2024 a Phase 1/2a metastatic Renal Cell Carcinoma study that will also include combination with immune checkpoint inhibitors. Our treatments are designed as one-time monotherapies, but with the additional potential, when used in combination, to significantly enhance the efficacy of other approved therapeutics.
Genenta was founded in 2014 as a spin-off of the San Raffaele Hospital in Milan.
The co-founders are: Pierluigi Paracchi, Chairman and CEO; Luigi Naldini, M.D., Ph.D., a pioneer in the development and application of lentiviral vectors (derived from HIV) for gene transfer, also Director of the Telethon Institute for Gene Therapy (SR-TIGET) at San Raffaele and full Professor at San Raffaele University. Bernhard Gentner, M.D., Ph.D. Associate Professor of Immuno-Oncology at Ludwig Institute for Cancer Research, Lausanne.
- In 2015, Genenta completed its first capital raise (Series A), followed by Series B in 2017 and Series C in 2019, securing a total of €33.6 million.
- In 2021, Genenta went public on the Nasdaq stock exchange with the ticker symbol: GNTA, raising an additional $37 million, becoming the only Italian-based company currently listed on the U.S. technology market.
- In 2023, Genenta received Orphan Drug Designation for Temferon from both the European Commission and the U.S. Food and Drug Administration.
